Multimodal treatment concepts of local radiation therapy with immunotherapy. Rationale for combination therapy and possible clinical treatment strategies

被引:1
|
作者
Eckert, Franziska [1 ]
机构
[1] Med Univ Wien, Klin Radioonkol, CCC Wien, AKH, Wahringer Gurtel 18-20, A-1090 Vienna, Austria
来源
UROLOGIE | 2022年 / 61卷 / 12期
关键词
Urogenital cancer; Radiotherapy; Oligometastases; Immune checkpoint inhibitors; Stereotactic; body radiotherapy;
D O I
10.1007/s00120-022-01966-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Immunotherapy has been established in the treatment of cancer in general and specifically in uro-oncology. The rationale to combine these therapies with radiotherapy is based on the biological effects of irradiation, which exceed the "physical" properties of irradiation to kill tumor cells. Depending on radiation dose and fractionation as well as tumor model or tumor entity used, irradiation can lead to immune stimulation or immune inhibition. As immune response is not limited to the local tumor microenvironment but occurs on a systemic level, a successful anticancer immune response after irradiation of one metastasis can lead to systemic tumor control (abscopal effect). Clinical trials test combination regimens in locally advanced tumors in the curative setting to improve survival rates and in the metastatic setting to prolong survival in palliative treatment. In addition, radiotherapy is used for local treatment of oligometastases and oligoprogression under palliative systemic therapy.
引用
收藏
页码:1324 / 1331
页数:8
相关论文
共 50 条
  • [1] The combination of radiation therapy and immunotherapy for genitourinary cancer treatment: rationale, current evidence, and prospects
    Ishihara, Dan
    Iyengar, Puneeth
    Meyer, Jeffrey
    Timmerman, Robert
    Choy, Hak
    Hannan, Raquibul
    JOURNAL OF RADIATION ONCOLOGY, 2015, 4 (04) : 355 - 363
  • [2] Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment
    Ishihara, Dan
    Pop, Laurentiu
    Takeshima, Tsuguhide
    Iyengar, Puneeth
    Hannan, Raquibul
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (03) : 281 - 298
  • [3] Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment
    Dan Ishihara
    Laurentiu Pop
    Tsuguhide Takeshima
    Puneeth Iyengar
    Raquibul Hannan
    Cancer Immunology, Immunotherapy, 2017, 66 : 281 - 298
  • [4] Rationale for combination therapy in the treatment of hypertension
    Sica, DA
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2002, 3 (02) : 63 - 65
  • [5] Radiation therapy and immunotherapy-a potential combination in cancer treatment
    Asna, N.
    Livoff, A.
    Batash, R.
    Debbi, R.
    Schaffer, P.
    Rivkind, T.
    Schaffer, M.
    CURRENT ONCOLOGY, 2018, 25 (05) : E454 - E460
  • [6] Clinical outcomes and timing on the combination of focal radiation therapy and immunotherapy for the treatment of brain metastases
    Antelo, Gabriela
    Comas, Silvia
    Casas, Francesc
    Valduvieco, Izaskun
    Barreto, Tanny
    Laplana, Maria
    Mases, Joel
    Oses, Gabriela
    Molla, Meritxell
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [8] Therapy with Bach bloods in multimodal treatment concepts
    Leopold-Temmler, B
    PRAKTISCHE TIERARZT, 2005, 86 (09): : 636 - +
  • [9] Understanding responses to targeted therapy and immunotherapy in melanoma: Rationale for combination strategies
    Cooper, Zachary A.
    Reuben, Alexandre
    Spencer, Christine
    Austin-Breneman, Jacob
    Jiang, Hong
    Chen, Pei-Ling
    Haymaker, Cara
    Amaria, Rodabe N.
    Tetzlaff, Michael T.
    Flaherty, Keith T.
    Chin, Lynda
    Dwyer, Karen C.
    Wargo, Jennifer A.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2015, 36 : S104 - S104
  • [10] Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results
    Zion, Adrienne S.
    Izzo, Joseph L., Jr.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2011, 9 (04) : 421 - 427